.png "Tetraphase (NASDAQ: TTPH)")
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Tetraphase (NASDAQ: TTPH) today and set a price target of $6. The company’s shares closed yesterday at $3.15, close to its 52-week low of $2.05.
Arce commented:
“and Likely Commercial Uptake in cIAI; Affirm Buy Stock Data 05/03/2018 Price $3.15 Exchange NASDAQ Price Target $6.00 52-Week High $8.75 52-Week Low $2.05 Enterprise Value (M) $45.3 Market Cap (M) $163 Public Market Float (M) 37.5 Shares Outstanding (M) 51.6 3 Month Avg Volume 1,678,640 Short Interest (M) 3.41 Shares Outstanding (M): Figure shown is as of May 2, 2018. Balance Sheet Metrics Cash (M) $117.7 Total Debt (M) $0.0 Total Cash/Share $2.28 Book Value/Share $1.93 Cash (M): Figure shown is as of March 31, 2018. EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.46) (0.79) (0.42)A 2Q (0.47) (0.83) (0.37) 3Q (0.58) (0.63) (0.31) 4Q (0.61) (0.46) (0.24) FY (2.11) (2.63) (1.32) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 2.0 1.5 1.9A 2Q 1.2 1.6 2.0 3Q 0.9 4.1 1.8 4Q 1.1 2.5 1.5 FY 5.1 9.7 7.2 10 8 6 4 2 0 MAY-17 SEP-17 JAN-18 MAY-18 20 15 10 5 0 Vol. (mil) Price Making it official.”
According to TipRanks.com, Arce is a 5-star analyst with an average return of 18.5% and a 40.8% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Collegium Pharmaceutical, and Conatus Pharmaceuticals.
Tetraphase has an analyst consensus of Moderate Buy, with a price target consensus of $6.60.
See today’s analyst top recommended stocks >>
Based on Tetraphase’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $2.53 million and GAAP net loss of $23.48 million. In comparison, last year the company earned revenue of $1.49 million and had a GAAP net loss of $29.46 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.
